In this context, this study highlights the interest of the combination of an EGFR inhibitor with a BH3-mimetic molecule in two ovarian cancer cell lines (IGROV1-R10 and OVCAR-3) and suggests that this strategy might prove useful in improving the therapeutic care of ovarian carcinoma. This evidence concerns the gene EGFR and ovarian cancer.